^
    Back
    Association details:
    Biomarker:MET mutation
    Cancer:Renal Cell Carcinoma
    Drug:Cometriq (cabozantinib capsule) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

    Excerpt:
    To evaluate the prognostic and predictive value of MET mutations, MET copy number or other markers of MET signaling in patients with mPRCC treated with putative MET inhibitors.
    Trial ID:
    PAPMET
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    Cabozantinib (Cabo) in advanced non-clear cell renal cell carcinoma (nccRCC): A retrospective multicenter analysis.

    Published date:
    05/16/2018
    Excerpt:
    Of the 7 evaluable papillary RCCs with MET alterations, 5 (71%) achieved CB.
    DOI:
    10.1200/JCO.2018.36.15_suppl.4579
    Trial ID:
    PAPMET